Skip to main content
Premium Trial:

Request an Annual Quote

Former Pharmacopeia Exec Named COO, President of Senomyx

NEW YORK, May 8 – Saiid Zarrabian, who resigned as chief operating officer at Pharmacopeia in December, has been appointed president and COO of Senomyx, a developer of flavor and fragrance molecules that can be used in consumer products, Senomyx said Tuesday.

"Mr. Zarrabian brings tremendous knowledge to Senomyx, particularly in the area of chemical and biological simulations and analysis systems, as well as drug discovery process,” Senomyx CEO Paul Grayson said in a statement.

“I am confident Mr. Zarrabian's wealth of experience and strong leadership skills will bring Senomyx closer to our goal of being the leader in the discovery of proprietary technology for consumer-based products," said Grayson.

At Pharmacopeia, Zarrabian helped to build the company both organically and through mergers and acquisitions, said Senomyx, which is based in La Jolla, Calif.

Zarrabian will replace Grayson in the role of president.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.